Loading
CMG제약 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest was filed 07 Jul 2026.
CMG제약: what insiders have been doing
CMG제약 belongs to the Health Care sector. Filings by its managers are published through DART (FSS). The last twelve months, up to 18 October 2026, brought 2 filings signed by 2 insiders.
The flow runs one way only: 1 insider bought (1 purchase) and nobody sold on the market. The amount is not disclosed for 1 filing. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 major shareholder among the declarants.
The clock since the last published purchase (7 July 2026) now reads 103 days.
Across the 2,630 companies tracked on its exchange, the median is 7 filings; at 2 filings, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed 1 purchase and 1 sale.
Other companies in the same sector with recent insider buying flagged by our signals: MAIA Biotechnology, Inc. and Cooper Companies, Inc. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Insider Decl.
8
Thresholds
n/a
Buy Volume
n/a
1 ops. · all time
Sell Volume
n/a
1 ops. · all time
Who traded when
BuySale오라이언자산운용1 buy
포워드-Nbh신기술사업투자조합제1호1 sale
Since the insiders bought
- -37.4%Entry ₩0 · Close at T+90 ₩0
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 21,002 of 24,148 companies
25.2
score / 100
Value9
Quality42
FCF yld-53%
Earn yld-12%
EV/EBITDA·
ROE2.3%
Gross mgn58%
Net mgn-9.6%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
₩562
Analyst consensus
Income statement
Revenue₩105.2B
Gross profit₩60.9B58% margin
EBITDA-₩5.6B-5% margin
Net income-₩10.1B4.0% margin
Valuation
Beta0.43
Balance sheet & cash
Market cap₩83.2B
Total debt₩72B
Free Cash Flow-₩44B
Debt / Equity34%
Profitability & ownership
ROE2.3%
ROA-0.7%
% insiders24.2%
% institutions2.1%
Last declaration on 7 July 2026
Declarations14 total
Other
Other
Other
Other
Other
Other
2,179,031 sharesKRXDART:20250609000247
14 of 14 declarations
About CMG제약
CMG제약 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It specializes in the development and commercialization of pharmaceutical products.
